respiratory
ILD

Promising results for treprostinil in pulmonary hypertension associated with ILD

Inhaled treprostinil shows some promise as a treatment for pulmonary hypertension associated with ILD, according to US research. The study randomised 326 patients to treprostinil (0.6 mg per ml) or placebo delivered by a nebuliser four times daily for 16 weeks. Doses were escalated from three to a maximum tolerated dose of up to 12 ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic